aclarubicin and Thrombocythemia--Essential

aclarubicin has been researched along with Thrombocythemia--Essential* in 1 studies

Other Studies

1 other study(ies) available for aclarubicin and Thrombocythemia--Essential

Article	Year
Low-dose aclarubicin in blastic transformation of essential thrombocythemia. Annals of hematology, 1991, Volume: 62, Issue:5 We attempted treatment with low-dose aclarubicin (ACR), a new anthracycline, in a 66-year-old man with blastic transformation of essential thrombocythemia (ET). Two courses of ACR (20 mg/day x 7 days) were given intravenously. He showed a good response to this therapy without severe side effects. He has since maintained a state of prolonged remission. These observations indicate that low-dose ACR may be beneficial for management of the blastic transformation of ET. Topics: Aclarubicin; Blast Crisis; Granulocytes; Humans; Male; Middle Aged; Thrombocythemia, Essential	1991

Article

Year

Low-dose aclarubicin in blastic transformation of essential thrombocythemia.

Annals of hematology, 1991, Volume: 62, Issue:5

We attempted treatment with low-dose aclarubicin (ACR), a new anthracycline, in a 66-year-old man with blastic transformation of essential thrombocythemia (ET). Two courses of ACR (20 mg/day x 7 days) were given intravenously. He showed a good response to this therapy without severe side effects. He has since maintained a state of prolonged remission. These observations indicate that low-dose ACR may be beneficial for management of the blastic transformation of ET.

Topics: Aclarubicin; Blast Crisis; Granulocytes; Humans; Male; Middle Aged; Thrombocythemia, Essential

1991